SLIL files IND on new cancer drug SL11047

7 May 2001

SLIL Biomedical has filed an Investigational New Drug application in theUSA for its lead candidate drug, SL11047 for the treatment of AIDS-related lymphoma, seeking approval to start a Phase I/II trial to assess tolerability to increasing doses in ARL patients.

SL11047 is a new-generation polyamine analog which is thought to act by attaching to DNA and preventing cells from dividing. First-generation drugs of this kind were limited by toxicity concerns, but SLIL's president and chief executive, Peter Molloy, says that the company "now has other second- and third-generation polyamine compounds," and a pipeline of more than a dozen lead compounds. Its second candidate drug, SL11093, is in preclinical development for prostate cancer.

SLIL says that if SL11047 proves to be well-tolerated and effective in the treatment of ARL, it will seek fast-track US Food and Drug Administration review with a view to launching the drug in 2004.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight